微信关注
China
Total item
Cart Subtotal
￥ 0.00 JAK / Stat
-
CO-1686 (Rociletinib, AVL-301)
Catalog No. A13028 EGFR 抑制剂CO-1686是一种新型的口服靶向共价（不可逆）抑制剂，可抑制表皮生长因子受体（EGFR）的致癌突变形式，目前正在研究用于治疗非小细胞肺癌（NSCLC）。 了解更多 -
Icotinib Hydrochloride
Catalog No. A13718 EGFR 抑制剂Icotinib hydrochloride是一种有效的特异性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI），IC（50）为5 nM，包括EGFR（L858R），EGFR（L861Q），EGFR（T790M）和EGFR的突变体（T790M，L858R）。 了解更多 -
AZD-9291 (Osimertinib)
Catalog No. A13681 EGFR 抑制剂AZD-9291 (Osimertinib)是第三代EGFR抑制剂，在临床前研究中显示出希望，并为已对现有EGFR抑制剂产生耐药性的晚期肺癌患者提供了希望。 了解更多 -
Tyrphostin AG 183
Catalog No. A13588 -
Poziotinib
Catalog No. A13044 EGFR 抑制剂Poziotinib是一种口服生物利用的，基于喹唑啉的泛表皮生长因子受体（EGFR或HER）抑制剂，具有潜在的抗肿瘤活性。 了解更多 -
EGFR Inhibitor
Catalog No. A13673 EGFR 抑制剂EGFR inhibitor是一种可透过细胞的4,6-二取代嘧啶化合物，可选择性抑制EGFR激酶，在体外的IC50值为21 nM，可阻断细胞中的受体自身磷酸化。 了解更多 -
Compound 56
Catalog No. A14953 -
Afatinib dimaleate
Catalog No. A14985 -
Erlotinib mesylate
Catalog No. A15081 -
Gefitinib hydrochloride
Catalog No. A15093 EGFR 抑制剂Gefitinib hydrochloride是一种EGFR抑制剂，可通过靶细胞中的表皮生长因子受体（EGFR）中断信号传导。因此，它仅在EGFR突变和过度活跃的癌症中有效。 了解更多 -
Vandetanib trifluoroacetate
Catalog No. A15272 -
WHI-P180
Catalog No. A15509 -
D-69491
Catalog No. A15457 -
AZD3759
Catalog No. A15551 -
ASP8273 (Naquotinib)
Catalog No. A14408 irreversible EGFR 抑制剂ASP8273 (Naquotinib)是不可逆的，第三代，选择性突变的表皮生长因子受体（EGFR）抑制剂，具有潜在的抗肿瘤活性。 了解更多 -
EGF816 (Nazartinib)
Catalog No. A14416 -
CL-387785 (EKI-785)
Catalog No. A13146 -
AG-18 (Tyrphostin 23)
Catalog No. A15940 -
DM1-SMCC
Catalog No. A15955 -
PD168393
Catalog No. A12725 -
EAI045
Catalog No. A16193 -
Anlotinib
Catalog No. A16253 -
PD158780
Catalog No. A16254 -
ARRY-380 (Irbinitinib)
Catalog No. A16413 -
Avitinib (AC0010)
Catalog No. A16826 irreversible EGFR 抑制剂Avitinib (AC0010)是一种基于吡咯并嘧啶的不可逆EGFR抑制剂，对EGFR L858R/T790M双重突变具有突变选择性，IC50值为0.18 nM，效力比野生型EGFR（IC50值为7.68 nM）高近43倍。它具有可比的抗肿瘤活性和耐受的毒性。 了解更多 -
Lazertinib (YH25448,GNS-1480)
Catalog No. A16827 EGFR 抑制剂Lazertinib (YH25448,GNS-1480)是一种有效的，高度突变选择性和不可逆的EGFR-TKI，对于Del19/T790M，L858R/T790M，Del19，Del19，IC50值分别为1.7 nM，2 nM，5 nM，20.6 nM和76 nM。L85R和野生型EGFR分别显示出更高的IC50值，即抗药性ErbB2和ErbB4。 了解更多 -
Tyrphostin AG-528
Catalog No. A17072 -
Pyrotinib Racemate
Catalog No. A17068 -
-
最新产品
AG-494
Catalog No. A17142 -
-
Lavendustin A
Catalog No. A17119 -
RG14620
Catalog No. A18327 -
Mutated EGFR-IN-2
Catalog No. A18565 EGFR 抑制剂Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=??1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. 了解更多 -
CHMFL-EGFR-202
Catalog No. A12524 EGFR inhibitorCHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. 了解更多 -
EGFR-IN-3
Catalog No. A15847 -
Canertinib dihydrochloride
Catalog No. A11344 EGFR inhibitorCanertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. 了解更多
FILTER BY:
Filtering:
- 作用机制: Inhibitor (抑制剂) 删除该内容
购物选项
- 分类
- 靶点
-
- Aurora A (1)
- Aurora B (1)
- CDK (2)
- CDK2 (1)
- CDK4 (1)
- EGFR (24)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FGFR1 (1)
- FLT3 (6)
- HDAC (1)
- HER2 (2)
- JAK1 (18)
- JAK2 (37)
- JAK3 (17)
- Mnk1 (1)
- Mnk2 (1)
- PDGFRβ (1)
- Pim1 (9)
- Pim2 (7)
- Pim3 (5)
- PKCα (1)
- PKCβ (1)
- RET (1)
- STAT1 (1)
- STAT3 (7)
- STAT5 (2)
- Syk (2)
- Tyk2 (5)
- VEGFR2 (FLK1) (2)
- VEGFR3 (FLT4) (1)
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
ADOOQ 产品质量保证
We promise all products to perform as described.